ARGENX SE-ADR Current Ratio 2017-2021 | ARGX

Current and historical current ratio for ARGENX SE-ADR (ARGX) from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. ARGENX SE-ADR current ratio for the three months ending June 30, 2021 was .
ARGENX SE-ADR Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $2.87B $0.24B 11.74
2021-03-31 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-12-31 $1.54B $0.18B 8.59
2019-06-30 $1.08B $0.12B 9.38
2018-12-31 $0.68B $0.05B 14.29
2018-06-30 $0.42B $0.03B 13.16
2017-12-31 $0.42B $0.03B 14.14
2017-06-30 $0.20B $0.04B 5.16
2016-12-31 $0.11B $0.05B 2.40
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $15.975B $0.042B
argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71